Drugs / HM12470
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03332849 | Jul 2015 → Apr 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03330327 | Mar 2015 → Aug 2017 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02302443 | Jan 2015 → May 2017 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-06-03 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 퀀텀프로젝트 등 당뇨신약 ADA 발표 hanmi.co.kr ↗
주1회 투여가능한 LAPSInsulin115의 특별한 프로파일: 매우 느린 수용체 작용, Human Insulin과 유사한 수용체 해리, 지속적인 수용체 활성화 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-06-03 | Hanmi Pharmaceutical Company Limited | <보도자료> 퀀텀프로젝트 등 당뇨신약 ADA 발표 hanmi.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM12470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03332849 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT02302443 ↗ |